So at $500 mil, how many patients will that enroll in phase lll? And, will this be for one or more indication? How many enrollees are considered a qualified group for test data integrity in phase lll? I would think Peregrine will partner with whoever provide them as much money to broaden the testing base to achieve the highest possible data success.
I imagine a deal would be structured similar to PCYC...they only had drugs in phase II and landed $150 million up front with up to $900 million possible.
So, $100-$200 million up front with similar milestones would make a lot of sense to me in partnering bavi. I think the partnership will already be priced in by the time of the announcement and expect we'll be around $1 billion market cap.
PCYC has negative earnings, just entered phase III and has a 4.5 billion market cap. IMO, if bavi works the potential dwarfs that of PCYC's lead candidate.
I agree... closer to 500 Million up front payment... My original estimate and will still stand by this estimate: of 400 M - 1 Billion re: due to the fact they are not just doing a phase III repeat of another "gold standard" phase trial but they will be running volume trials ( breast / pancreatic..etc..etc.. ) in order to bring "conclusive" data in line in order not to just go for AA but to have the possibility of Bavi being used across the board in as many indications as they can possibly bring data in for which is the reason they need atleast 400 Million to get this done right!
Big Pharma knows it as well.... whats the worst case scenario? It works for NSCLC and maybe data comes in great for a couple other indications vs great data volume wise across the board for 4/5/6/7/8 out of the top 20 cancers ? My opinion is Partnering is not the problem.... for PH. III NSCLC... the problem is who is willing to allow Peregrine to leap into 1st place and start reigning in the data for across the board cancers. Why wait for great #'s for NSCLC Phase III for another year plus... when they can run the table and really show the strength and potential that Bavi possesses.
I think they could landed a partner by now... but the loan was needed to further bring in a little bit more data by the numbers to really sell the Bavi platform as volume deep... again, this stock has the unbelievable potential of a rise that no other small biotech could even dream of. Its wait and see for now... next up... Sept. 7
Market Data 
Markets 
AI
